LU91117I2
Cetuximab in combination with irinotecan.
Abstract
Monoclonal antibodies and hybrid cell lines for production of monoclonal antibodies specific to the human epidermal growth factor receptor which are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors are provided. Therapeutic compositions containing these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.
Term
Term ended
Projected expiry passed 29 October 2024, 1.9 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
38 members in 10 offices
Priority claims9
| Document | Office | Kind | Date |
|---|---|---|---|
| 24473788 | United States of America | A | |
| 24473788 | United States of America | A | |
| 31910989 | United States of America | A | |
| 31910989 | United States of America | A | |
| 89117125 | European Patent Office (EPO) | A | |
| 89117125 | European Patent Office (EPO) | A | |
| EP19890117125 | – | – | – |
| US19880244737 | – | – | – |
| US19890319109 | – | – | – |
Members38
| Document | Office | Kind | |
|---|---|---|---|
| EP0359282A2 | European Patent Office (EPO) | A2 | |
| AU4128089A | Australia | A | |
| EP0359282A3 | European Patent Office (EPO) | A3 | |
| JPH02291295A | Japan | A | |
| EP0359282B1 | European Patent Office (EPO) | B1 | |
| AT123070T | Austria | T | |
| ATE123070T1 | Austria | T1 | |
| DE68922808D1 | Germany | D1 | |
| EP0667165A1 | European Patent Office (EPO) | A1 | |
| DE68922808T2 | Germany | T2 | |
| ES2075019T3 | Spain | T3 | |
| CA1340417C | Canada | C | |
| US6217866B1 | United States of America | B1 | |
| EP0667165B1 | European Patent Office (EPO) | B1 | |
| AT214943T | Austria | T | |
| ATE214943T1 | Austria | T1 | |
| JP2002114710A | Japan | A | |
| DE68929384D1 | Germany | D1 | |
| ES2174859T3 | Spain | T3 | |
| DE68929384T2 | Germany | T2 | |
| JP3600617B2 | Japan | B2 | |
| LU91116I2 | Luxembourg | I2 | |
| LU91117I2This record | Luxembourg | I2 | |
| DE122004000040I1 | Germany | I1 | |
| DE122004000041I1 | Germany | I1 | |
| JP2005047934A | Japan | A | |
| NL300166I1 | Netherlands (Kingdom of the) | I1 | |
| NL300167I1 | Netherlands (Kingdom of the) | I1 | |
| JP3732426B2 | Japan | B2 | |
| JP4122393B2 | Japan | B2 | |
| LU91448I2 | Luxembourg | I2 | |
| LU91449I2 | Luxembourg | I2 | |
| NL300350I1 | Netherlands (Kingdom of the) | I1 | |
| NL300351I1 | Netherlands (Kingdom of the) | I1 | |
| NL300353I1 | Netherlands (Kingdom of the) | I1 | |
| DE122008000028I1 | Germany | I1 | |
| DE122008000030I1 | Germany | I1 | |
| DE122008000027I1 | Germany | I1 |
Numbers
- Publication, DOCDB
- 91117
- Publication, EPODOC
- LU91117I
- Application
- 91117
- Application, DOCDB
- 91117
- Application, EPODOC
- LU20040091117C
Titles
- English
- Cetuximab in combination with irinotecan.
Classification
- CPC, 6
- C07K16/2863
- A61K38/00
- A61K39/395
- A61P35/00
- A61P43/00
- A61K33/243
- IPC, 11
- A61K31 704
- A61K33 243
- A61K38 00
- A61K39 395
- A61P35 00
- A61K45 00
- A61P43 00
- C07K16 28
- C07K16 30
- C12P21 08
- C12R1 91